Tempus AI enters multiyear agreement with Bristol Myers Squibb to license oncology data through 2031

Tempus AI has entered a multiyear agreement with Bristol Myers Squibb for BMY to license multimodal oncology data through 2031, supporting biological and clinical insight identification, novel drug target discovery and therapeutic development across its oncology portfolio.

Detected & updated continuously · Source: Nebula